معرفی
Bertrand Jean-Claude serves as a Senior Scientist at the Research Institute of the McGill University Health Centre (RI-MUHC) at the Glen site and holds a Professorship in the Department of Medicine within McGill University's Faculty of Medicine and Health Sciences. His primary affiliation lies with the Metabolic Disorders and Complications Program under the Centre for Translational Biology.
His research centers on innovative anticancer drug development, specifically focusing on the design and synthesis of multitargeted drug candidates engineered to simultaneously block multiple pathways in tumor cells. Key methodologies include kinase inhibitor development, molecular modeling, and pharmacokinetic analysis of combi-drugs—hybrid molecules designed for dual mechanisms of action such as EGFR receptor inhibition coupled with DNA damage.
His publication history reveals consistent contributions to molecular oncology, with recent work emphasizing
- EGFR and DNA repair pathway dual targeting
- Fluorescence-based drug distribution tracking
- Overcoming P-glycoprotein-mediated drug resistance
- Stable combi-molecule fragmentation mechanisms
Jean-Claude maintains active laboratory operations within the RI-MUHC's Centre for Translational Biology, where his team investigates combi-targeting strategies for oncology applications. His research program receives support through institutional frameworks of McGill University and the RI-MUHC, with emphasis on translating molecular discoveries into preclinical therapeutic candidates.